Probiotec Ltd
ASX:PBP
Intrinsic Value
Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. [ Read More ]
The intrinsic value of one PBP stock under the Base Case scenario is 3.96 AUD. Compared to the current market price of 2.84 AUD, Probiotec Ltd is Undervalued by 28%.
Valuation Backtest
Probiotec Ltd
Run backtest to discover the historical profit from buying and selling PBP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Probiotec Ltd
Current Assets | 72.6m |
Cash & Short-Term Investments | 12.8m |
Receivables | 34.7m |
Other Current Assets | 25.1m |
Non-Current Assets | 158.8m |
PP&E | 61.2m |
Intangibles | 84.1m |
Other Non-Current Assets | 13.5m |
Current Liabilities | 46m |
Accounts Payable | 30.7m |
Other Current Liabilities | 15.3m |
Non-Current Liabilities | 97.1m |
Long-Term Debt | 79.1m |
Other Non-Current Liabilities | 18m |
Earnings Waterfall
Probiotec Ltd
Revenue
|
221.2m
AUD
|
Cost of Revenue
|
-155m
AUD
|
Gross Profit
|
66.3m
AUD
|
Operating Expenses
|
-46.2m
AUD
|
Operating Income
|
20m
AUD
|
Other Expenses
|
-11.3m
AUD
|
Net Income
|
8.7m
AUD
|
Free Cash Flow Analysis
Probiotec Ltd
PBP Profitability Score
Profitability Due Diligence
Probiotec Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Probiotec Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
PBP Solvency Score
Solvency Due Diligence
Probiotec Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Probiotec Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PBP Price Targets Summary
Probiotec Ltd
According to Wall Street analysts, the average 1-year price target for PBP is 3.06 AUD with a low forecast of 3.03 AUD and a high forecast of 3.15 AUD.
Shareholder Return
PBP Price
Probiotec Ltd
Average Annual Return | 10.07% |
Standard Deviation of Annual Returns | 15.12% |
Max Drawdown | -13% |
Market Capitalization | 231m AUD |
Shares Outstanding | 81 323 400 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-11-14. The firm owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. The Company’s products are manufactured on behalf of a range of clients, including international companies. The company also owns Multipack-LJM business, a contract packer, providing packing services for a range of pharmaceutical, consumer healthcare, cosmetics and food, and beverage companies. The firm subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Biotech Pharmaceuticals Australia Pty Ltd, Biotech Pharmaceuticals Pty Ltd, Probiotec (NSW) Pty Ltd, Australian Dairy Proteins Pty Ltd, Milton Pharmaceuticals Pty Ltd and Willie Labs Generics Pty Ltd.
Contact
IPO
Employees
Officers
The intrinsic value of one PBP stock under the Base Case scenario is 3.96 AUD.
Compared to the current market price of 2.84 AUD, Probiotec Ltd is Undervalued by 28%.